Aperçu du dossier

In a closely watched pharmaceutical patent battle, Novo Nordisk A/S and Lupin Limited resolved a multi-patent infringement dispute over the blockbuster obesity and diabetes drug Saxenda® (liraglutide recombinant) in just 259 days—without a single trial day. Filed on July 27, 2023, in the U.S. District Court for the District of New Jersey (Case No. 1:23-cv-04031), the action was dismissed without prejudice on April 11, 2024, following a negotiated resolution between the parties.

At stake were 16 U.S. patents protecting Novo Nordisk’s liraglutide injection franchise, one of the most commercially significant GLP-1 receptor agonist products on the market. Lupin’s Abbreviated New Drug Application (ANDA) No. 218382—seeking generic approval before patent expiry—triggered the lawsuit under the Hatch-Waxman Act framework.

For patent litigators, ANDA practitioners, and pharmaceutical R&D teams, this case underscores the continuing strategic importance of pre-trial settlement in complex, multi-patent pharmaceutical disputes and the formidable IP moat Novo Nordisk has constructed around its liraglutide portfolio.

Les parties

Les brevets en cause

The dispute centered on 16 U.S. patents spanning formulation chemistry, drug delivery mechanisms, and therapeutic methods related to liraglutide:

• • US8,114,833 — Formulation/Composition Patent
• • US8,684,969 — Formulation/Composition Patent
• • US8,920,383 — Formulation/Composition Patent
• • US9,457,154 — Formulation/Composition Patent
• • US10,220,155 — Formulation/Composition Patent
• • US9,108,002 — Device/Delivery System Patent
• • US9,132,239 — Device/Delivery System Patent
• • US9,616,180 — Device/Delivery System Patent
• • US9,687,611 — Device/Delivery System Patent
• • US9,775,953 — Device/Delivery System Patent
• • US10,357,616 — Device/Delivery System Patent
• • US10,376,652 — Device/Delivery System Patent
• • US11,097,063 — Device/Delivery System Patent
• • US11,311,679 — Device/Delivery System Patent
• • US9,861,757 — Additional Patent
• • USRE46,363 — Additional Patent

This layered patent portfolio—spanning application numbers from 2006 through 2019—reflects a classic “patent thicket” strategy protecting multiple aspects of Saxenda®’s commercial lifecycle.

Le verdict et l'analyse juridique

Résultat

On April 11, 2024, the court entered a stipulated dismissal without prejudice of all claims, counterclaims, and affirmative defenses between Novo Nordisk and Lupin concerning all 16 patents-at-issue. Each party agreed to bear its own attorneys’ fees and costs—a standard feature of negotiated pharmaceutical patent settlements. No damages were awarded, and no injunctive relief was formally adjudicated by the court.

Analyse des causes du verdict

The action was initiated as a Hatch-Waxman patent infringement action—a statutory cause of action arising under 35 U.S.C. § 271(e)(2), wherein the act of filing an ANDA with a Paragraph IV certification constitutes constructive patent infringement. Novo Nordisk did not need to demonstrate actual commercial infringement; Lupin’s ANDA filing alone triggered the right to litigate.

Critically, the stipulated order explicitly preserves Lupin’s right to maintain its Paragraph IV certification to the patents-at-issue in ANDA No. 218382. This is a legally significant carve-out: Lupin retains its challenge posture against these patents and remains eligible to receive FDA final approval of its ANDA. This provision strongly suggests the settlement included a confidential license or entry date agreement—a common Hatch-Waxman resolution mechanism—rather than a capitulation by either party.

The District of New Jersey also retained jurisdiction to enforce the settlement terms, providing a judicial backstop for any future disputes between the parties on the same subject matter.

Signification juridique

The dismissal without prejudice is strategically meaningful. Unlike a dismissal with prejudice, it preserves Novo Nordisk’s right to reassert these patents should Lupin’s commercial conduct or ANDA status materially change. It also leaves the patent validity questions unanswered by any court—a deliberate outcome preserving Novo Nordisk’s deterrence value for future ANDA challengers.

The preservation of Lupin’s Paragraph IV rights signals the parties reached a licensing arrangement with a negotiated market entry date—standard in Hatch-Waxman litigation where branded companies grant authorized generic entry upon patent expiry or at an agreed future date.

Points stratégiques à retenir

For Patent Holders: Novo Nordisk’s 16-patent thicket strategy demonstrates the value of layered patent portfolios protecting formulation, method, and device claims across multiple prosecution timelines. Maintaining overlapping patent families extending into the 2030s significantly raises the cost and complexity of ANDA challenges.

For Accused Infringers: Lupin’s retention of its Paragraph IV certification—despite settlement—indicates that ANDA filers need not surrender their challenge rights to resolve litigation favorably. Negotiating authorized entry dates while preserving ANDA status is a viable and often preferred resolution pathway.

For R&D Teams: Generic developers targeting GLP-1 receptor agonist drugs face formidable, multi-layered IP estates. Freedom-to-operate (FTO) analyses must account not only for active compound patents but formulation stability, delivery device, and dosing method claims—each representing an independent litigation trigger.